Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA
Veru Inc. (VERU)
Last veru inc. earnings: 2/12 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
verupharma.com/investors
Company Research
Source: GlobeNewswire
— VERU-100 Is a Proprietary Peptide Formulation Designed with Multiple Beneficial Clinical Attributes Addressing the Shortfalls of the Current Multi-Billion-Dollar Androgen Deprivation Therapy Market — — Reached Agreement with FDA on an Expedited Regulatory Pathway and Clinical Development Strategy — MIAMI, June 04, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced that it has added to its robust prostate cancer drug development pipeline, a proprietary biologic drug candidate, VERU-100, for the treatment of hormone sensitive advanced prostate cancer, an established multi-billion-dollar global market. VERU-100 was internally developed in collaboration with Drug Delivery Experts, LLC of San Diego, California (DDE Labs). “The target product profile for VERU-100 is most compelling having a number of advantages over currently
Show less
Read more
Impact Snapshot
Event Time:
VERU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERU alerts
High impacting Veru Inc. news events
Weekly update
A roundup of the hottest topics
VERU
News
- Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop [Yahoo! Finance]Yahoo! Finance
- Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory WorkshopGlobeNewswire
- Global Contraceptive Devices Market is Set to Accelerate at a CAGR of ~6% by 2032, as Demand for Advanced Birth Control Solutions Rises | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Veru to Present Two Abstracts at ObesityWeek 2025GlobeNewswire
- Veru Announces Pricing of $25 Million Public OfferingGlobeNewswire
VERU
Earnings
- 8/12/25 - Miss
VERU
Sec Filings
- 10/30/25 - Form 8-K
- 10/30/25 - Form 424B5
- 10/29/25 - Form 424B5
- VERU's page on the SEC website